Financial instruments - Collaboration and License Agreement (Details) $ in Thousands |
6 Months Ended | 12 Months Ended | 19 Months Ended | |
|---|---|---|---|---|
|
Dec. 31, 2015
USD ($)
customer
|
Jun. 30, 2015
customer
|
Jun. 30, 2014
customer
|
Dec. 31, 2015
USD ($)
|
|
| Collaboration and License Agreement | ||||
| Number of customers | customer | 1 | 1 | 1 | |
| GlaxoSmithKline Intellectual Property Development Ltd | Collaborative arrangement | ||||
| Collaboration and License Agreement | ||||
| Impairment losses | $ 0 | |||
| Amounts past due | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Number of customers. No definition available.
|
| X | ||||||||||
- Definition Amounts past due. No definition available.
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|